Costs and Cost-effectiveness of Subcutaneous DMPA through Different Delivery Channels: What the Evidence Tells Us
Recent evidence from African countries indicates that DMPA-SC may help reduce service delivery costs by catalyzing community-based distribution and remote provision of injectable contraception. Moreover, self-injection of DMPA-SC—when compared with clinic administration of traditional injectables—is not just cost-effective but cost saving when accounting for costs to both women and health systems.
New evidence shows that women who self-inject DMPA-SC continue using injectable contraception longer than those who receive injections from providers, which translates to fewer unintended pregnancies.
More Trending Topic Self-Care resources
- Self-Care: A Cost Effective Solution for Maternal, Newborn & Child Health for All
- WHO Consolidated Guideline on Self-care Interventions for Health: Sexual and Reproductive Health and Rights
- Who Self-Cares Wins
- Self-Care: Better Daily Health for Individuals and Societies
- Advocacy Roadmap- Igniting a Self-Care Movement for Sexual and Reproductive Health
- Self-Care Quality of Care Framework
- Home-Based Care Reference Guide for COVID-19
- Acceleration of Self-Care in the Time of COVID-19
- Going Online to Accelerate the Impact of HIV Programs
- COVID-19, Maternal and Child Health, Nutrition – What Does the Science Tell Us?
- Is Contraceptive Self-injection Cost-effective Compared to Contraceptive Injections from Facility-Based health Workers? Evidence from Uganda
- Self-Care in Sexual and Reproductive Health and Rights: A New Frontier in Healthcare
- Journey to DMPA-SC in the Sahel
- Supporting Menstrual Regulation through the Call Centre in Bangladesh
- Lessons Learned about the Introduction of Sayana Press in Madagascar